SYDNEY, Feb. 4, 2015 /PRNewswire/ -- EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV nanocell platform for the targeted delivery of cancer therapeutics and other therapeutic molecules, announced today that the Company is scheduled to present at the BIO CEO & Investor Conference taking place in New York City on February 9-10, 2015.
Dr. Himanshu Brahmbhatt and Dr. Jennifer MacDiarmid, Joint-CEOs of EnGeneIC, will be attending the conference, and Himanshu will provide an overview of the Company’s business during a live presentation. Both will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
Event: | BIO CEO & Investor Conference | |
Date: | Monday, February 9, 2015 | |
Time: | 9:30 a.m. (Eastern Time) | |
Location: | Waldorf Astoria, New York, NY |
About EnGeneIC, Ltd.
EnGeneIC is an emerging biopharmaceutical company focused on developing its proprietary EDV nanocell platform for the targeted delivery of cancer therapeutic and other therapeutic molecules. The company’s lead technology platform, EDV utilizes antibody-targeted, bacterially derived, non-living “nanocells” to release high concentrations of chemotherapeutic agents, molecularly targeted drugs, and RNA-interference molecules directly into targeted tumor cells. In doing so, EDVTM nanocells enable current cancer treatments to be more potent and far less toxic, while also offering a potential new means for treating drug-resistant cancers. EnGeneIC is currently preparing an IND for FDA submission, with plans to launch a Phase1/2a clinical trial in recurrent glioblastoma patients in early 2015. Trials are also in planning stages for non-small cell lung cancer.
For more information please visit www.engeneic.com
About BIO CEO & Investor Conference
The 17th annual BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
For EnGeneIC:
Jennifer MacDiarmid, Ph.D.
Joint-CEO and Director
jmacdiarmid@engeneic.com
+61-2-9420-5833
Anjan Chatterji, MBA, J.D., LL.M
EVP Corporate Development
achatterji@engeneic.com
+1-917-484-1977
Investor / Media Contacts:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. / Amy S. Wheeler
+1-212-375-2664 / +1-646-362-5750
jdrumm@tiberend.com / awheeler@tiberend.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/engeneic-to-present-at-bio-ceo--investor-conference-2015-300030129.html
SOURCE EnGeneIC, Ltd.
Help employers find you! Check out all the jobs and post your resume.
